URISTOP

Important safety and use flags

• Scope boundary: this score covers only urinary incontinence associated with urethral sphincter incompetence in bitches; efficacy is demonstrated only in ovariohysterectomised bitches. It does not cover behavioural urination, every male/intact dog or undifferentiated leakage.
• Diagnose before treating: classify storage versus voiding disease and assess history, examination, urinalysis/culture and post-void residual or imaging as indicated. In bitches under 1 year investigate ectopic ureter or another anatomic disorder; also exclude infection, polyuria and neurologic disease.
• Exact volume: after accurate weighing give 0.1 ml/5 kg PO three times daily on food. Do not substitute the ACVIM 2 mg/kg q8-12h or US tablet regimens for this product-specific syrup instruction.
• Salt/base audit: the leaflet calls the dose 1 mg phenylpropanolamine/kg, but 0.02 ml/kg x 40.28 mg/ml equals 0.8056 mg/kg free base and x 50 mg/ml equals 1 mg/kg hydrochloride. Preserve the unambiguous labelled volume; do not generate a different volume from the ambiguous active name.
• Measure systolic blood pressure before treatment and periodically. Reassess or stop for sustained hypertension, tachycardia/arrhythmia, marked restlessness/aggression, collapse, ataxia, seizure, significant vomiting/diarrhoea, appetite/weight loss, proteinuria or polyuria/polydipsia.
• Use particular caution in cardiovascular disease, severe renal or hepatic insufficiency, diabetes mellitus, hyperadrenocorticism, glaucoma, hyperthyroidism or another metabolic disorder. Hypertension-prone patients may warrant an estrogen-first strategy or more frequent monitoring.
• Do not use with non-selective monoamine oxidase inhibitors. Review other sympathomimetics, anticholinergics, tricyclic antidepressants and selective MAO-B inhibitors because cardiovascular/CNS effects can be amplified.
• Do not use during pregnancy or lactation. No compatibility studies support mixing with another veterinary medicine. Hypersensitivity to phenylpropanolamine or an excipient is a contraindication.
• Response and duration are individualized: record wet episodes and adverse effects, then reassess rather than issuing automatic indefinite repeats. Failure or relapse requires diagnosis/adherence review and a planned alternative or combination strategy—not unsupervised dose escalation.
• Human safety is critical: replace the child-resistant cap immediately, never leave a filled syringe unattended and keep the bottle away from children. Overdose can cause hypertension, agitation, insomnia, nausea or headache and may be fatal, especially in children; accidental ingestion needs immediate medical advice. Wash and fully dry the dosing syringe; discard three months after opening.